First-Line Pharmacologic Therapy for Symptomatic Compression Fractures

Acute Pain Management (0-5 Days)

Calcitonin provides rapid symptomatic relief and is specifically recommended for acute presentation, with nasal calcitonin 200 IU or calcitonin suppositories 200 IU reducing pain in a clinically significant manner at 1, 2, 3, and 4 weeks, according to the American College of Physicians 1
The use of calcitonin for acute symptomatic osteoporotic compression fractures is supported by guideline-level evidence, with a strong recommendation for its use in this context 1

The American College of Physicians provides a strong recommendation for bisphosphonates as initial pharmacologic treatment for primary osteoporosis, based on high-certainty evidence, with alendronate and risedronate being specifically recommended as first-choice agents due to favorable tolerability, low cost, and extensive clinical experience 2
Bisphosphonates demonstrate reduction in vertebral fractures, non-vertebral fractures, and hip fractures, with a significant reduction in new vertebral fractures and clinical symptomatic fractures, according to the American College of Physicians 2, 3
The evidence supporting bisphosphonates is robust, with a favorable balance among benefits, harms, patient values/preferences, and cost compared to other osteoporosis medications, as recommended by the American College of Physicians 2

Zoledronic acid (intravenous bisphosphonate) is appropriate for patients with oral intolerance, dementia, malabsorption, or non-compliance, as recommended by the European League Against Rheumatism 3
Ibandronate is recommended to prevent additional symptomatic fractures in patients with existing vertebral compression fractures, according to the American College of Physicians 1

The American College of Physicians suggests denosumab for postmenopausal females with contraindications to bisphosphonates, with a conditional recommendation and moderate-certainty evidence 2
Denosumab can be considered for patients with refractory bone pain or worsening bone mineral density despite bisphosphonate therapy, as recommended by the National Osteoporosis Foundation 4

Adequate calcium intake of 1000-1200 mg/day together with vitamin D 800 IU/day should be provided when using anti-osteoporosis drugs, with vitamin D supplementation being associated with a 15-20% reduction in non-vertebral fractures and falls, according to the National Osteoporosis Foundation 3, 4

Monitor for osteonecrosis of the jaw and atypical femoral fractures, with higher risk after longer treatment duration, as recommended by the American Dental Association and the American College of Physicians 2
Monitor for renal dysfunction with chronic bisphosphonate use, with regular follow-up and assessment of kidney function, as recommended by the National Kidney Foundation 5, 6
Bisphosphonates are typically prescribed for 3-5 years, and longer in patients who remain at high risk, with systematic follow-up being essential for long-term adherence to drug treatment, according to the European League Against Rheumatism 3
For patients at very high risk of fracture, anabolic agents such as teriparatide or romosozumab may be considered, with a conditional recommendation, as suggested by the American College of Physicians and the National Osteoporosis Foundation 2, 3